Determined to realize a future in which people with cancer live longer and better than ever before

Syndax

4Q21 EARNINGS PRESENTATION

Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

2021: Transformative year for Syndax

Initiated AGAVE-201 and AUGMENT-101 pivotal trials

Signed global partnership with Incyte for axatilimab

Presented robust data for SNDX-5613 & axatilimab at ASH

Completed $86.5 M financing

High value growth through pipeline development and continued asset acquisition

SNDX-5613: Menin-MLL disruption

Expand beyond R/R acute leukemia

- Pivotal trials (AUGMENT) ongoing in NPM1 / MLLr acute leukemia
- Initiate combo trials (ven/aza, chemo), explore maintenance

Axatilimab: Anti-CSF-1R

Expand into earlier lines of cGHVD and fibrotic disease

- Pivotal (AGAVE) trial ongoing
- Initiate Phase 2 IPF trial
- Est. Incyte global partnership with 50:50 US profit split

Pipeline expansion

- Expand pipeline through BD
  - Targeting assets in late pre-clin to Phase 1
  - Strong balance sheet to support BD efforts

AUGMENT-101 registration trials underway in 3 distinct patient populations

AUGMENT-101

R/R MLLr or mNPM1 acute leukemia

Dose: 163mg BID with any strong CYP3A4 inhibitor

Independent, pivotal trials

- 64 adults + up to 10 peds → **AUGMENT-101-2A: MLLr ALL**
- 64 adults + up to 10 peds → **AUGMENT-101-2B: MLLr AML**
- 64 adults + up to 10 peds → **AUGMENT-101-2C: NPM1 mut AML**

Primary endpoint: CR/CRh*
Secondaries: Durability of CR/CRh, OS, transfusion independence

**** Patients taken to HSCT can restart treatment with SNDX-5613 post-Transplant***

Trials testing expanded opportunities for SNDX-5613 to initiate in 1H22

BEAT-AML: Frontline Ven/Aza combo

Phase 1/3; Frontline mNPM1 or MLLr AML

SNDX-5613 + Ven/Aza



Primary Endpoints:

- RP2D of combo
- CR/CRh rate, MRD- rate, OS

AUGMENT-102: R/R Chemo combo

Phase 1; Relapsed or refractory mNPM1 or MLLr AML/ALL

SNDX-5613 + chemo



Primary Endpoints:

- Safety, tolerability, RP2D of combo

INTERCEPT: MRD-progression in AML

Phase 1; Beyond frontline mNPM1 or MLLr AML/ALL

SNDX-5613



Primary Endpoints:

- MRD- rate

SNDX-5613: moving into frontline meaningfully expands market potential with additional patients and increasing duration of Tx

Potential best/first-in-class agent

- Clear efficacy in refractory, advanced NPM1 and MLLr acute leukemia
- High percentage of MRD negative responses

Profile supports use in frontline and maintenance

- Well-tolerated safety profile, no discontinuations due to treatment related AE
- Preclinical data supports combos with venetoclax[1], chemotherapy[2]
- Pediatric formulation established



1. Carter, B., et al., Blood 2021, 2. Data on file

AGAVE-201 : ongoing global pivotal trial for axatilimab in chronic GVHD

Inclusion criteria:

- 6 years and older
- Recurrent or refractory active cGVHD after at least 2 lines of systemic therapy



Primary Endpoint: Objective Response Rate (ORR) by 2014 NIH GVHD Criteria

Key Secondaries: Duration of response, improvement in modified Lee Symptom Scale

Partnership with Incyte enables expansion into additional high value indications and new geographies



1. SmartImmunology Insights cGVHD report March 2020; 2. SmartImmunology Insights IPF report March 2020. * IPF trial will be conducted and funded by Syndax

Proven ability to build the pipeline

Business development continues to be a core strength of our business

Clinical development leadership enables competitive advantage

Established relationships enhance identification and access to quality assets

From UCB

Axatilimab

From Allergan/Vitae

Menin-MLL inhibitors



Financial highlights, 1Q 2022 and FY 2022 financial guidance

Ticker	SNDX (NASDAQ)
Cash and short-term investments (as of December 31, 2021)	$439.9 million
Shares Outstanding* (as of December 31, 2021)	59.0 million

2022 Operating Expense Guidance		
	Q1 2022	FY 2022
Research and Development	$30-35 million	$130-140 million
Total Operating Expenses^	$38-42 million	$160-170 million

* *Includes 55.0 million common shares and pre-funded warrants to purchase 4.0 million common shares;*
^ *Includes ~$14 million non-cash stock compensation expense for the full year*

Thank you. Questions?

Syndax